🔹 1. Absorption 🧃
Statins are well absorbed from the gastrointestinal tract after oral administration.
But they undergo extensive first-pass metabolism in the liver.
👉 This means only a portion reaches systemic circulation.
Highly protein-bound (≈95–99%), mainly to albumin 🧬
Distribute well to the liver (primary site of action) and to some extent to muscle tissue.
Most statins are metabolized in the liver by cytochrome P450 (CYP450) enzymes:
CYP3A4: 🟡 Atorvastatin, Simvastatin, Lovastatin
CYP2C9: 🔵 Rosuvastatin, Fluvastatin
Pravastatin is mostly not metabolized by CYP450 — ⛔ fewer drug interactions!
Primarily biliary excretion (via feces 💩)
Minimal renal clearance (except Pravastatin and Rosuvastatin — 💧 partially renal)
Varies widely:
⏱️ Short-acting: Simvastatin (~2–3 hrs), Lovastatin
⌛ Long-acting: Atorvastatin (~14 hrs), Rosuvastatin (~19 hrs)
🔁 Long half-life = once-daily dosing = better compliance 😊
Myalgia (muscle pain/soreness)
Myopathy (muscle weakness + elevated CK)
Rhabdomyolysis (🛑 rare but life-threatening muscle breakdown)
🩸 Leads to kidney damage due to release of myoglobin
🔍 Watch for dark urine and muscle pain
Rare cases of memory loss, confusion, or foggy thinking
Usually reversible 🧠✅
↑ Liver enzymes (ALT, AST) in 1–3% of patients
Rarely: hepatitis or liver failure
🧪 Monitor LFTs regularly!
Nausea, abdominal pain, constipation, diarrhea
Mild and usually transient 🚽
Slight ↑ risk of new-onset type 2 diabetes
(especially at higher doses) 🍩➡️🩸
Skin rash, itching (rare)
May cause angioedema or anaphylaxis in extreme cases ⚠️
📌 Before starting statins:
✅ Liver function tests (ALT, AST)
✅ Baseline Creatine Kinase (CK) if muscle risk present
📌 During treatment:
🔄 Repeat LFTs if symptoms occur
🚨 Report muscle pain, weakness, or dark urine immediately
SUMMARY
Parameter | Description |
---|---|
Absorption | Well absorbed orally but undergo significant first-pass metabolism |
Distribution | Highly protein-bound (95–99%), especially to albumin |
Metabolism | Mainly in the liver via CYP450 enzymes: |
- **CYP3A4**: Atorvastatin, Simvastatin, Lovastatin
- **CYP2C9**: Rosuvastatin, Fluvastatin |
| Excretion | Primarily via bile and feces; minimal renal excretion
(except pravastatin and rosuvastatin have some renal clearance) |
| Half-life | Varies:
- Short: Simvastatin (~2–3 hrs), Lovastatin
- Long: Atorvastatin (~14 hrs), Rosuvastatin (~19 hrs) |
System | Effect |
---|---|
Musculoskeletal | Myalgia, myopathy, muscle cramps, rhabdomyolysis (rare but serious) |
Hepatic | Elevated liver enzymes (ALT, AST); rarely hepatotoxicity |
Gastrointestinal | Nausea, constipation, abdominal pain |
Metabolic | Slightly increased risk of new-onset diabetes mellitus |
Neurological | Rare cases of memory loss or confusion |
Hypersensitivity | Rash, pruritus (uncommon) |
Monitoring Required:
Liver function tests (LFTs) before initiation and during therapy
Creatine kinase (CK) if muscle symptoms occur